Minnesota Based Company Cleared to Commercialize Tissue Organ Transplant and Bio Material Solutions in United States, Australia, and New Zealand
Recombinetics, an innovative gene-editing and gene-repair company, announced the issuance of new patents today. The newly issued patents are the latest evidence that the future of scientific breakthroughs for the biomedical market is being developed through its technologies and proprietary TALEN gene-editing platforms.
U.S. Patent (No. 8309791 B2) has been issued for a method that dramatically enhances the efficiency and flexibility of gene addition in livestock cells and embryos using chemically treated transposons, a genome modification platform developed by Recombinetics scientists. Patents have also been issued in New Zealand (No. 565337) and Australia (No. 2006262020) for the seminal application of transposon transgenesis to swine, wherein pigs were engineered to prevent transmission of viruses to humans. In addition to global commercial applications including product development for the therapeutic transplantation of cells and organs such as islets, hearts, kidneys, and livers, the technology may have implications for the improvement of global infectious disease management for population health.
“We’re excited to see our IP portfolio grow. Related patents are pending around the world,” said Scott Fahrenkrug, Chairman and Chief Executive Officer of Recombinetics. “We are confident that the breakthroughs protected in these patents will lead to clinically impactful and profitable commercial applications for the organ transplant and bio-materials markets, which is estimated at $2 billion and growing.”
Recombinetics is currently seeking private investors in support of its continued development and growth. In addition to these newly issued patents, the company has several landmark patents pending in genetic engineering, including a Utility patent for its gene editing, gene-repair technology. This patent solidifies Recombinetics’ position in TALEN-based gene editing, for which they hold a global, exclusive license from Cellectis Bioresearch for application to livestock for biomedicine and animal agriculture.
“We get excited any time we can enhance scientific processes and platforms that promise to improve patient outcomes, contribute to solving world hunger and provide for the more humane treatment of animals as a food source,” concluded Fahrenkrug. “Patent protection motivates capital investment. Capital leads to more solutions, strategic partnerships, customer acquisition and organizational growth.”
Founded in 2008, Recombinetics, Inc. is a global innovator in proprietary precision gene repair and gene editing technology. Breakthrough scientific research – including the development of TALEN technologies- has resulted in global exclusive rights in the biomedical, animal agriculture and livestock vertical markets. Recombinetics has garnered both private sector funding and significant development contracts from the National Institutes of Health, the US Department of Agriculture and the global commercial leaders in livestock genetics.